<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ICU</journal-id>
<journal-id journal-id-type="hwp">spicu</journal-id>
<journal-title>ICU Director</journal-title>
<issn pub-type="ppub">1944-4516</issn>
<issn pub-type="epub">1944-4524</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1944451612444444</article-id>
<article-id pub-id-type="publisher-id">10.1177_1944451612444444</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Evidence Based Management</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Acute Liver Failure</article-title>
<subtitle>Current Evidence-Based Management for ICU Care</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yarema</surname><given-names>Tania C.</given-names></name>
<degrees>MS, RN, ACNP-BC</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Marshall</surname><given-names>Carrie T.</given-names></name>
<degrees>MS, APRN, ACNP-BC</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Cucina</surname><given-names>Amy Salgado</given-names></name>
<degrees>MS, RN, ACNP-BC</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Dodge</surname><given-names>Heather</given-names></name>
<degrees>MS, RN, ACNP-BC</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Imhoff</surname><given-names>Barbara</given-names></name>
<degrees>RN, MS, ACNP-BC</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Judy</surname><given-names>Jonathan</given-names></name>
<degrees>MS, RN, ACNP-BC</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Peterson</surname><given-names>Jennifer</given-names></name>
<degrees>MSN, RN, ACNP-BC</degrees>
</contrib>
<aff id="aff1-1944451612444444">Critical Care Services, California Pacific Medical Center, San Francisco, California</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1944451612444444">Tania C. Yarema, MS, RN, ACNP-BC, Acute Care Nurse Practitioner, Critical Care Services, Californai Pacific Medical Center, P.O. Box 7999, San Francisco, CA 94120; e-mail: <email>yaremat@sutterhealth.org</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>3</issue>
<fpage>116</fpage>
<lpage>124</lpage>
<permissions>
<copyright-statement>© 2012 The Author(s)</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Acute liver failure (ALF) is a rare and potentially life-threatening condition; the mortality rate for ALF remains high because of the rapid progression of the syndrome. A large number of etiologies such as drugs (acetaminophen being most common), viruses (hepatitis A and B), and autoimmune and metabolic causes can lead to ALF, but in a significant percentage of cases no exact etiology is determined. As the disease progresses to the life- threatening stage, management of these critically ill patients requires meticulous attention to their hemodynamic and neurologic condition and to other complications that can arise. This review describes the typical presentation of ALF and discusses its diagnosis and etiologies. The laboratory and radiologic hallmarks of the diagnosis are also described. The authors also evaluate the evidence for a variety of therapeutic maneuvers that have been put forward to ameliorate the course of ALF. Ultimately, given its often inexorable course, orthotopic liver transplant may become necessary. At this time, treatment with orthotopic liver transplant provides the only reliable life-saving treatment for progressive ALF.</p>
</abstract>
<kwd-group>
<kwd>acute liver failure</kwd>
<kwd>fulminant hepatic failure</kwd>
<kwd>intensive care treatment</kwd>
<kwd>subacute hepatic failure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p><bold>Case History:</bold> <italic>A 26-year-old, previously healthy woman was admitted to our liver transplant center from a community hospital where she presented with recent altered mental status and jaundice. She was found to have an elevated bilirubin of 32 mg/dL, international normalized ratio of 6.2, arterial ammonia of 96 µg/dL, and significantly elevated liver transaminases. She had no history of acetaminophen or other toxic ingestions, including alcohol; no <italic>recent</italic> viral conditions or an existing condition related to hepatic impairment or severe coagulopathy. Hepatic viral serologies, autoimmune markers, and ceruloplasm levels were negative. Over the next 12 hours, the patient’s mental status deteriorated, requiring endotracheal intubation to protect her airway. A head computed tomography scan showed no evidence of cerebral edema, and transjugular biopsy of the liver revealed massive hepatic necrosis. The patient was diagnosed with acute liver failure of unknown etiology and managed in the intensive care unit for &lt;48 hours until she received an orthotopic liver transplantation. Her postoperative transplantation course was unremarkable, and she was discharged from the hospital on postoperative day 8</italic>.</p>
<p><disp-quote>
<p>“Despite advanced developments in medicine, the mortality rate for ALF [acute liver failure] remains high because of the rapid progression of the syndrome.”</p>
</disp-quote></p>
<sec id="section1-1944451612444444" sec-type="intro">
<title>Introduction</title>
<p>Acute liver failure (ALF) is a rare and potentially life-threatening condition, affecting an estimated 2000 patients per year in the United States.<sup><xref ref-type="bibr" rid="bibr1-1944451612444444">1</xref></sup> The fictitious case described above is a typical presentation for ALF. Despite advanced developments in medicine, the mortality rate for ALF remains high because of the rapid progression of the syndrome. In addition, the exact cause of ALF may never be established, contributing to the mysterious nature of the syndrome. To date, the only therapy with proven benefit is orthotopic liver transplantation (OLT). Management of these patients while awaiting OLT can be extremely challenging and are best served by admission to the ICU of a tertiary transplant center for close monitoring and status 1A listing, if appropriate. This review takes an organ system approach to discuss the workup, management, and current modalities of treatment for ALF.</p>
<p>In the 1970s, fulminant hepatic failure (FHF) was originally defined as a coagulation abnormality such as an increased international normalized ratio (INR) of greater than or equal to 1.5 combined with symptoms of mental deterioration without preexisting cirrhosis occurring in a timeframe of less than 24 weeks.<sup><xref ref-type="bibr" rid="bibr2-1944451612444444">2</xref></sup> This definition has been revised over the years to include classifications that recognize the severity of the syndrome based on prognostic factors such as etiology, onset of hepatic encephalopathy, severity of jaundice and coagulopathy, intracranial pressure (ICP), and survival rate without OLT.<sup><xref ref-type="bibr" rid="bibr3-1944451612444444">3</xref></sup> This newer terminology from O’Grady et al<sup><xref ref-type="bibr" rid="bibr3-1944451612444444">3</xref></sup> is shown in <xref ref-type="table" rid="table1-1944451612444444">Table 1</xref> and classifies patients as hyperacute, acute, and subacute liver failure.</p>
<table-wrap id="table1-1944451612444444" position="float">
<label>Table 1.</label>
<caption>
<p>Classification of Acute Liver Failure<sup><xref ref-type="bibr" rid="bibr3-1944451612444444">3</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-1944451612444444" xlink:href="10.1177_1944451612444444-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Hyperacute liver failure</td>
<td>7-day progression from jaundice to encephalopathy associated with severe coagulopathy and increased intracranial pressure</td>
</tr>
<tr>
<td>Acute liver failure</td>
<td>8- to 28-day progression from jaundice to encephalopathy, moderate coagulopathy, and increased intracranial pressure</td>
</tr>
<tr>
<td>Subacute liver failure</td>
<td>5- to 12-week progression to jaundice and encephalopathy. Jaundice more profound than coagulopathy. Indolent course</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section2-1944451612444444">
<title>Etiology</title>
<p>Acetaminophen overdose is the most common cause of ALF in the United States.<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref>,<xref ref-type="bibr" rid="bibr5-1944451612444444">5</xref></sup> In 2002, Ostapowicz et al<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref></sup> published a prospective cohort study of 308 patients with ALF enrolled across 17 tertiary care centers in the United States; acetaminophen overdose accounted for 39% of their cases. Of these, 37% were intentional overdoses, 57% were accidental, and 7% were indeterminate.<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref></sup> ALF due to acetaminophen overdose is dose related. Ingestions of &gt;10 g/d are closely associated with ALF.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> In the study by Ostapowicz et al,<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref></sup> the average ingestion was 13.2 g/d with 99 of the 120 patients ingesting more than 4 g/d.</p>
<p>In addition to acetaminophen, idiosyncratic drug reactions account for up to 13% of ALF in the United States.<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref></sup> These drugs include over-the-counter and prescription drugs such as antibiotics, nonsteroidal anti-inflammatory agents, and herbal medicines.<sup><xref ref-type="bibr" rid="bibr5-1944451612444444">5</xref>,<xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> Drug reactions as a cause of ALF can be difficult to determine and a diagnosis may be made by exclusion.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> ALF in the setting of idiosyncratic drug reactions usually occurs within 6 months after drug therapy has started; rarely does ALF occur more than 1 to 2 years after starting a potentially hepatotoxic drug.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup></p>
<p>Viral hepatitis is known to account for as much as 12% of ALF.<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref>,<xref ref-type="bibr" rid="bibr7-1944451612444444">7</xref></sup> The most common viral causes are hepatitis A and B, which account for 4% and 8% of cases, respectively.<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref>,<xref ref-type="bibr" rid="bibr7-1944451612444444">7</xref></sup> Surprisingly, in the study by Ostapowicz et al,<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref></sup> there were no cases of ALF caused by hepatitis C. ALF caused by hepatitis B may also occur with immunosuppressive treatment such as chemotherapy.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup></p>
<p>In the study by Ostapowicz et al, acute ischemic liver injury was reported in 6% of cases. This condition is also known as “shock liver” and may occur following periods of profound hypotension or hypovolemia.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> It is essential to correct the underlying cause of shock in order to reduce long-term liver injury, and although transplant is seldom indicated, the 1- to 2- year outlook for these patients.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup></p>
<p>Autoimmune hepatitis (AIH) and Wilson’s disease were reported in 4% and 3%, respectively, of ALF cases in the study by Ostapowicz et al. AIH often presents as a very severe form of ALF. Although steroid therapy is recommended, their effects can be deleterious if concomitant multiorgan failure is present.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> Wilson’s disease is seen predominately in a younger patient population, and does not a commonly present with ALF. Approximately 5% of patients diagnosed with Wilson’s disease develop ALF. Early diagnosis of Wilson’s disease is critical as it is generally fatal without transplantation due to the complications and rapid progression of the disease.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref>,<xref ref-type="bibr" rid="bibr8-1944451612444444">8</xref></sup></p>
<p>A specific cause of ALF cannot be discovered in the remaining 15% to 17% of cases.<sup><xref ref-type="bibr" rid="bibr4-1944451612444444">4</xref>,<xref ref-type="bibr" rid="bibr5-1944451612444444">5</xref></sup> Generally, indeterminate cases are thought to be due to an inadequate or incomplete history regarding drug or toxin exposure.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> <xref ref-type="table" rid="table2-1944451612444444">Table 2</xref> lists the most likely reported etiologies for ALF.</p>
<table-wrap id="table2-1944451612444444" position="float">
<label>Table 2.</label>
<caption>
<p>Etiologic Agents Causative of Acute Liver Failure<sup><xref ref-type="bibr" rid="bibr9-1944451612444444">9</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-1944451612444444" xlink:href="10.1177_1944451612444444-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Drug-related causes (~50%)</td>
<td>Toxin-related causes</td>
</tr>
<tr>
<td> Acetaminophen (most common, ~42%)</td>
<td> <italic>Amanita phalloides</italic> mushroom toxin</td>
</tr>
<tr>
<td> Chronic ETOH use can precipitate</td>
<td> <italic>Bacillus cereus</italic> toxin</td>
</tr>
<tr>
<td> Antibiotics (ampicillin-clavulanate, ciprofloxacin, doxycycline,   erythromycin, isoniazid, nitrofurantoin, tetracycline)</td>
<td> Cyanobacteria toxin</td>
</tr>
<tr>
<td> Salicylates (Reye syndrome)</td>
<td>Metabolic causes</td>
</tr>
<tr>
<td> Lipid-lowering medications (statins)</td>
<td> α-1 antitrypsin deficiency</td>
</tr>
<tr>
<td> Antidepressants (amitriptyline, nortriptyline)</td>
<td> Wilson disease</td>
</tr>
<tr>
<td> Antiepileptics (phenytoin, valproate)</td>
<td> Reye syndrome</td>
</tr>
<tr>
<td> Immunosuppressive agents (cyclophosphamide, methotrexate)</td>
<td>Vascular causes</td>
</tr>
<tr>
<td> Nonsteroidal anti-inflammatory drugs (NSAIDs)</td>
<td> Budd–Chiari syndrome (hepatic vein thrombosis)</td>
</tr>
<tr>
<td> Anesthetic agents (halothane)</td>
<td> Portal vein thrombosis</td>
</tr>
<tr>
<td>Herbal or alternative medicine causes</td>
<td> Hepatic arterial thrombosis (posttransplant)</td>
</tr>
<tr>
<td> Ginseng</td>
<td>Malignant causes</td>
</tr>
<tr>
<td> Pennyroyal oil</td>
<td> Primary liver tumor</td>
</tr>
<tr>
<td> Kawakawa</td>
<td> Secondary liver tumor from metastases, lymphoma,   leukemia</td>
</tr>
<tr>
<td> Chaparral or germander tea</td>
<td>Causes during pregnancy</td>
</tr>
<tr>
<td>Viral causes</td>
<td> Acute fatty liver of pregnancy</td>
</tr>
<tr>
<td> Viral hepatitis (A and B are majority, C rarely causes acute   liver failure)</td>
<td> Hemolysis, elevated liver enzymes, low platelet count   (HELLP; rarely fulminant)</td>
</tr>
<tr>
<td> Hepatitis E in endemic areas</td>
<td>Other</td>
</tr>
<tr>
<td> Hepatitis D as a coinfection or superinfection with hepatitis B</td>
<td> Indeterminate/cryptogenic (~15%)</td>
</tr>
<tr>
<td> Cytomegalovirus</td>
<td/>
</tr>
<tr>
<td> Herpes simplex virus</td>
<td/>
</tr>
<tr>
<td> Epstein–Barr virus</td>
<td/>
</tr>
<tr>
<td> Paramixovirus</td>
<td/>
</tr>
<tr>
<td> Hemorrhagic fever viruses</td>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section3-1944451612444444">
<title>Diagnostic Studies Indicating Prognosis</title>
<p>The ability to accurately diagnose ALF greatly depends on a comprehensive health history. Arriving at a precise diagnosis will lead to the most appropriate treatment plan and improve the chances for a favorable outcome. Urgent hospitalization with ICU care in a liver transplant facility is mandatory if hyperacute or acute liver failure is suspected because of the rapid progression of the syndromes. Initial diagnostic tests and prognostic indicators to evaluate the severity as well as the etiology of ALF are shown in <xref ref-type="table" rid="table3-1944451612444444">Table 3</xref>. Simultaneously, the patient’s candidacy for OLT should be rapidly evaluated.</p>
<table-wrap id="table3-1944451612444444" position="float">
<label>Table 3.</label>
<caption>
<p>Initial Workup for Patients Presenting With Acute Liver Failure</p>
</caption>
<graphic alternate-form-of="table3-1944451612444444" xlink:href="10.1177_1944451612444444-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Thorough history from patient and/or family</td>
<td>Include all medications OTC/herbals, wild mushroom ingestion, depression/suicidality, clarify first symptom onset, alcohol/drugs, viral syndrome, and recent travel</td>
</tr>
<tr>
<td>Baseline laboratories</td>
<td>Hepatic panel (evaluation for chronic liver disease), CBC, PT/INR, comprehensive metabolic panel, complete toxicology screen, factor V level, AFP, arterial lactate, ABG, arterial ammonia level, acetaminophen level, amylase/lipase, blood type x2, serum HCG if female</td>
</tr>
<tr>
<td>Baseline serologies</td>
<td>HBsAg, hepatitis Delta IgG if sAg +, HBcAb IgM, HAV IgM, HEV RNA in selected patients, HCV Ab, HIV Ab</td>
</tr>
<tr>
<td>Baseline microbiology</td>
<td>Blood cultures, urinalysis, urine culture</td>
</tr>
<tr>
<td>Other laboratories</td>
<td>ANA, anti-actin Ab, quant IgG level, anti-SLA, ceruloplasmin, 24-hour urine for copper<sup><xref ref-type="table-fn" rid="table-fn2-1944451612444444">a</xref></sup> HSV 1/2 IgM, EBV PCR, CMV PCR<sup><xref ref-type="table-fn" rid="table-fn3-1944451612444444">b</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1944451612444444">
<p>Abbreviations: OTC, over the counter; CBC, complete blood count; PT/INR, prothrombin time/international normalized ratio; AFP, α-fetoprotein; ABG, arterial blood gas; HCG, human chorionic gonadotropin; HBsAG, hepatitis B surface antigen; HAV, hepatitis A virus; HEV, hepatitis E virus; HCV, hepatitis C virus; Ab, antibody; ANA, antinuclear antibody; SLA, soluble liver antigen; HSV, herpes simplex virus; EBV, Epstein–Barr virus; CMV, cytomegalovirus; PCS, polymerase chain reaction.</p>
</fn>
<fn id="table-fn2-1944451612444444">
<label>a</label>
<p>Suggested labs for unknown etiology (seronegative acute liver failure)</p>
</fn>
<fn id="table-fn3-1944451612444444">
<label>b</label>
<p>If viral syndrome identified or suspected.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The ability to recover from ALF is linked to increased α-fetoprotein (AFP) levels and has been shown to have a favorable outcome in acetaminophen-induced liver injury.<sup><xref ref-type="bibr" rid="bibr9-1944451612444444">9</xref>,<xref ref-type="bibr" rid="bibr10-1944451612444444">10</xref></sup> In a prospective analysis by Schiodt et al<sup><xref ref-type="bibr" rid="bibr11-1944451612444444">11</xref></sup> in 2006, changes in AFP levels during ALF appear to have significant prognostic value. AFP levels are closely related to the characteristic pattern of injury for each etiology (such as apoptosis or necrosis) than to acuity of illness or the likelihood of survival.<sup><xref ref-type="bibr" rid="bibr11-1944451612444444">11</xref></sup></p>
<p>Coagulopathy is a characteristic feature of ALF that indicates decreasing production of clotting factors. Increasing factor V levels during the course of ALF have been shown to be a reliable predictor of recovery, whereas decreasing factor V levels predict impending deterioration.<sup><xref ref-type="bibr" rid="bibr12-1944451612444444">12</xref></sup> Therefore, routine daily measurement of factor V levels should be done on all patients presenting with ALF.</p>
<p>Ammonia is a known brain neurotoxin that accumulates during ALF. Increased ammonia levels are found in patients with ALF compared to those with compensated or even decompensated cirrhosis.<sup><xref ref-type="bibr" rid="bibr13-1944451612444444">13</xref></sup> In a prospective study, Bhatia et al<sup><xref ref-type="bibr" rid="bibr14-1944451612444444">14</xref></sup> found that elevated arterial ammonia levels, measured within 24 hours of presentation with ALF were associated with worse outcomes.</p>
<p>A thorough physical examination of neurological status, presence of abdominal pain, hepatosplenomegly, and jaundice are all clinically important when evaluating ALF. Acute on chronic liver failure should be ruled out initially, as management strategies are entirely dissimilar. <xref ref-type="table" rid="table3-1944451612444444">Table 3</xref> summarizes the comprehensive physical exam, laboratory data, and radiographic data that should be obtained when evaluating patients for ALF.</p>
</sec>
<sec id="section4-1944451612444444">
<title>Radiographic Studies</title>
<p>Various modalities of radiographic assessment, including computed tomography (CT), abdominal and chest X-rays, ultrasonography, fluoroscopy, and echocardiography prove to be extremely useful in determining the etiology of acute liver failure. They may also be essential examinations as part of pre– and post–liver transplant evaluation in those ALF patients who are eligible for OLT.</p>
<sec id="section5-1944451612444444">
<title>Computed Tomography</title>
<p>Computed tomography scans of the head and abdomen play an important role in the management of ALF. Head CT is useful for the diagnosis of cerebral edema, the most serious complication of ALF. It may also be used to follow the progression of cerebral edema during ALF, which will play a role in determining the eligibility of an individual for liver transplantation. CT scan of the abdomen with or without angiography can be necessary as part of screening for liver masses when the cause of liver failure by history, examination, and laboratory results is unclear.</p>
</sec>
<sec id="section6-1944451612444444">
<title>Ultrasound</title>
<p>Ultrasound is the least invasive hepatobiliary imaging tool. Doppler ultrasound is an important tool to assess portal blood flow and to rule out portal vein thrombosis as part of the workup for possible liver transplantation. It may also be used to detect and determine vascularity of hepatic masses identified by CT scan. However, ultrasound has limited utility in distinguishing different types of hepatomas<sup><xref ref-type="bibr" rid="bibr15-1944451612444444">15</xref></sup> and transjugular biopsy would be necessary to investigate further.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup></p>
</sec>
<sec id="section7-1944451612444444">
<title>Transjugular Liver Biopsy</title>
<p>Transjugular liver biopsy under (TJLB) may be necessary to assist in determining the etiology of ALF and is an important part of the workup in patients for whom OLT is a consideration. Biopsy can afford direct evidence of the type and severity of liver disorders causing ALF ranging from auto-immune and other types of hepatitis to the necrosis of acetaminophen-induced liver toxicity, Budd–Chiari syndrome, alcoholic and nonalcoholic steatohepatitis (fatty liver disease), primary biliary cirrhosis, primary sclerosing cholangitis, and hemochromatosis.<sup><xref ref-type="bibr" rid="bibr16-1944451612444444">16</xref></sup> It is particularly important in cases where auto-immune hepatitis, metastatic liver disease, lymphoma, or herpes simplex virus are suspect.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> Though other methods of liver biopsy exist (percutaneous, laparoscopic), at our center the transjugular route is nearly always the preferred method. Although more invasive than the percutaneous route, the TJLB can be safely performed in patients with the bleeding diatheses/coagulopathy of acute liver failure.<sup><xref ref-type="bibr" rid="bibr17-1944451612444444">17</xref>,<xref ref-type="bibr" rid="bibr18-1944451612444444">18</xref></sup> With a tissue sample obtained from within the vascular system, TJLB minimizes the risk of bleeding and involves a compressible vascular access point.</p>
</sec>
<sec id="section8-1944451612444444">
<title>Cardiac Catheterization</title>
<p>Cardiac catheterization is a second fluoroscopic procedure that merits mention in evaluating patients with ALF. In many cases (patients with coronary arterial disease or significant risk factors, abnormal cardiac stress tests, acute/severe volume overload, or other existing cardiopulmonary disease), right and left heart catheterization are necessary to investigate and evaluate the presence or absence of coronary artery disease and pulmonary arterial hypertension and to evaluate general cardiac function. This information will guide decision making about a patient’s ability to withstand the stress of a transplant from a cardiovascular standpoint and can mean the difference between approval and declination for transplant.</p>
</sec></sec>
<sec id="section9-1944451612444444">
<title>Management of Acute Liver Failure</title>
<sec id="section10-1944451612444444">
<title>Cerebral Edema</title>
<p>Neurological manifestations of ALF include encephalopathy, cerebral edema, and intracranial hypertension (ICH). These conditions are frequently seen and can represent the most serious complications associated with ALF. Some manifestations of cerebral edema and ICH include hyponatremia, asterixis, hyperammonemia, hyperreflexia, ankle clonus, worsening hepatic encephalopathy, and seizures.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref>,<xref ref-type="bibr" rid="bibr19-1944451612444444">19</xref></sup></p>
<p>Neuroimaging, including magnetic resonance imaging (MRI), CT scan, and transcranial dopplers (TCDs) can offer a noninvasive way to determine cerebral tissue involvement and evaluate for edema.<sup><xref ref-type="bibr" rid="bibr20-1944451612444444">20</xref></sup> CT scans are the preference for neurological imaging; it is easy to obtain the scan with quick results in the acutely ill patient. MRI offers the most information pertaining to brain tissue; however, most patients with ALF are critically ill and cannot leave the ICU for extended periods of time. TCD can measures cerebral blood flow velocity, which, when trended over time, can offer an insight into ICH. TCD is advantageous in that it can be performed at the bedside; however, it is not widely available. Finding a skilled professional to interpret TCD can also be challenging in smaller centers. All three of these tests are still being researched as to their reliability to determine accurate ICP.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref>,<xref ref-type="bibr" rid="bibr20-1944451612444444">20</xref></sup></p>
<p>The use of invasive methods of ICP monitoring remains controversial at this time and varies among transplant centers. It has been recommended by the American Association for the Study of Liver Disease (AASLD) that monitors be placed in patients with grade 3-4 encephalopathy in an effort to offer corrective therapy for elevated ICP. This includes treatment with mannitol and/or hypertonic saline to restore adequate cerebral perfusion pressure (CPP = MAP − ICP; MAP = mean arterial pressure) and avoid herniation.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> A goal of ICP &lt;25 mm Hg and CPP &gt;60 mm Hg should be targeted.<sup><xref ref-type="bibr" rid="bibr21-1944451612444444">21</xref></sup> The risks and benefits of placing an intracranial monitoring device should be weighed as this disposes the patient to serious complications, including infection and bleeding.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> Maintaining proper positioning of head of bed greater than 30° in a neutral position may also be helpful in patients with any grade of cerebral edema.</p>
<p>Worsening of neurologic symptoms such as decerebrate posturing and pupillary abnormalities may also be used to qualitatively assess the development of ICH. If ICH is identified, first-line therapy is administration of mannitol 0.5 to 1 mg/kg; this dose may be repeated once if there is not normalization of ICP after the initial bolus. Serum osmolality must be monitored during mannitol therapy, as its use has been associated with severe diuresis, acute renal failure, hyperkalemia, and hypotension. Caution should be exercised as the continued use can lead to rebound ICH.<sup><xref ref-type="bibr" rid="bibr22-1944451612444444">22</xref>,<xref ref-type="bibr" rid="bibr23-1944451612444444">23</xref></sup></p>
<p>After a serum osmolality of &gt;320 mOsm/L is reached or repeated doses of mannitol have failed to reduce ICH, then it is recommended to switch to hypertonic saline (3%) with a goal of serum sodium 145 to 155 mEq/L.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> Complications from prolonged use of hypertonic saline include hyperosmolality, hypernatremia, convulsion, congestive heart failure, hypokalemia, and metabolic acidosis.<sup><xref ref-type="bibr" rid="bibr24-1944451612444444">24</xref></sup> The AASLD does not recommend the use of hyperventilation or corticosteroids with elevated ICP. However, it does suggest that short-acting barbiturates and hypothermia with a goal core body temperature of 34°C to 35°C can be used as bridge to transplantation if all other therapies to reduce ICP have failed.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup></p>
</sec>
<sec id="section11-1944451612444444">
<title>Hypotension and Circulatory Collapse</title>
<p>Assessment and treatment of hypovolemia should occur before the initiation of vasopressor administration. Vasopressor support is recommended for severe systemic hypotension, defined by Stravitz et al<sup><xref ref-type="bibr" rid="bibr25-1944451612444444">25</xref></sup> as a systolic blood pressure &lt;90 mm Hg; MAP &lt;65 mm Hg, or to maintain a CPP equivalent to the recommended MAP of 50 to 80 mm Hg.<sup><xref ref-type="bibr" rid="bibr25-1944451612444444">25</xref></sup> The vasopressors of choice for treatment of hypotension after correction of hypovolemia are norepinephrine and dopamine. In patients with ALF and traumatic brain injury, norepinephrine may provide a more consistent cerebral perfusion response. Dopamine should not be given as a low-dose drip as it has not been shown to be effective in reducing the risk of renal injury in patients experiencing systemic inflammatory response syndrome and acute renal failure in ALF.<sup><xref ref-type="bibr" rid="bibr25-1944451612444444">25</xref></sup></p>
<p>Mesenteric perfusion may be compromised with the use of epinephrine in severe septic shock, thereby delivering less blood flow to the hepatic vasculature and worsening the liver failure. Vasopressin and other similar analogues are not recommended because of their cerebral vasodilatory effect, which may exacerbate increased intracranial hypertension.<sup><xref ref-type="bibr" rid="bibr25-1944451612444444">25</xref></sup></p>
</sec>
<sec id="section12-1944451612444444">
<title>Acute Kidney Injury and Other Metabolic Impairments</title>
<p>Acute kidney injury (AKI) is a common complication of ALF, occurring in 30% to 70% of patients. AKI is often associated with drug-induced etiologies such as acetaminophen overdose.<sup><xref ref-type="bibr" rid="bibr26-1944451612444444">26</xref>,<xref ref-type="bibr" rid="bibr27-1944451612444444">27</xref></sup> The pathophysiology remains unclear and multifactorial, often correlating with the etiology. Metabolic acidosis, hypotension from a systemic inflammatory response and decreased circulating vascular volume related to dehydration and coagulopathy, are contributing factors. Maintaining an adequate mean arterial pressure to ensure adequate renal perfusion with crystalloid resuscitation initially is recommended.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> However, after the patient has been resuscitated, the ASSLD recommends adding sodium bicarbonate to the maintenance fluid if acidosis is present. If renal replacement therapy is indicated for the volume overloaded or persistently acidotic patient, it has been recommended in clinical trials that it be done in continuous fashion rather than intermittently, to improve hemodynamic stability.<sup><xref ref-type="bibr" rid="bibr28-1944451612444444">28</xref></sup></p>
</sec>
<sec id="section13-1944451612444444">
<title><italic>N</italic>-Acetylcysteine</title>
<p><italic>N</italic>-Acetylcysteine (NAC) has long been a safe antidote to treat ALF caused by acetaminophen toxicity, effectively minimizing or halting further liver damage when administered within the first 24 hours after ingestion.<sup><xref ref-type="bibr" rid="bibr29-1944451612444444">29</xref><xref ref-type="bibr" rid="bibr30-1944451612444444"/>-<xref ref-type="bibr" rid="bibr31-1944451612444444">31</xref></sup> NAC has been shown to improve oxygen consumption, end-organ function, and survival when liver damage is already established.<sup><xref ref-type="bibr" rid="bibr32-1944451612444444">32</xref></sup> Rank et al<sup><xref ref-type="bibr" rid="bibr33-1944451612444444">33</xref></sup> showed the beneficial effect of NAC on hepatosplanchnic oxygen transport and liver blood flow in septic shock patients, demonstrating improved liver function and flow. Lee et al<sup><xref ref-type="bibr" rid="bibr34-1944451612444444">34</xref></sup> suggested that transplant-free survival was improved with NAC administration even in non-acetaminophen ALF patients, especially those with early-stage hepatic encephalopathy.</p>
<p>Administration of NAC for patients with ALF should begin with a dose of 140 mg/kg orally (PO) or per nasogastric tube, followed by 70 mg/kg PO every 4 hours for a suggested minimum of 17 doses (~60 hours) or until liver injury pattern has improved by 50% or more.<sup><xref ref-type="bibr" rid="bibr35-1944451612444444">35</xref></sup> NAC can also be given intravenously (if unable to tolerate orally) with initial loading dose of 150 mg/kg over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusion of 6.25 mg/kg/h for the remaining 67 hours or establishment of clear clinical improvement.<sup><xref ref-type="bibr" rid="bibr35-1944451612444444">35</xref></sup></p>
</sec>
<sec id="section14-1944451612444444">
<title>Corticosteroids</title>
<p>Hydrocortisone has been studied for the use of augmenting norepinephrine effect in hypotensive patients with ALF, sepsis, and relative adrenal insufficiency in moderate doses of 200 to 300 mg/d.<sup><xref ref-type="bibr" rid="bibr25-1944451612444444">25</xref></sup> Harry et al<sup><xref ref-type="bibr" rid="bibr36-1944451612444444">36</xref></sup> studied short synacthen test in 45 patients admitted to an ICU with acute hepatic dysfunction in 2002, and found that patients who were sicker, that is, required vasopressors, endotracheal intubation for hepatic encephalopathy, and OLT, had a significantly lower increment in short synacthen test response than patients who did not require these therapies and survived.</p>
</sec>
<sec id="section15-1944451612444444">
<title>Phenytoin Prophylaxis</title>
<p>Two recent studies that studied the prophylactic use of phenytoin for seizure prophylaxis in all patients with ALF produced conflicting data. In one a large population of patients with ALF and advanced encephalopathy was found to have nonconvulsive seizure activity. Propofol or benzodiazepine infusions that are used for sedation and seizure prophylaxis are not recommended at this time as studies have shown mixed results as to whether it may be a benefit or not.<sup><xref ref-type="bibr" rid="bibr25-1944451612444444">25</xref>,<xref ref-type="bibr" rid="bibr37-1944451612444444">37</xref></sup> One randomized controlled trial showed no difference in overall survival; however, it did reveal significant reduction of cerebral edema in the treated group.<sup><xref ref-type="bibr" rid="bibr37-1944451612444444">37</xref></sup> The AASLD does recommend that benzodiazepines should be used in phenytoin refractory cases in patients who are seizing.<sup><xref ref-type="bibr" rid="bibr37-1944451612444444">37</xref></sup></p>
</sec>
<sec id="section16-1944451612444444">
<title>Antibiotic Prophylaxis</title>
<p>Bacterial infections are complications in approximately 80% of patients who develop ALF.<sup><xref ref-type="bibr" rid="bibr38-1944451612444444">38</xref></sup> The most common infections include pneumonia in 50%, urinary tract infection in 22%, catheter-related bloodstream infections in 12%, and spontaneous bacteremia in 16% of patients. Gram-negative enteric bacilli and gram-positive cocci are the most frequently isolated bacteria, followed by Candida fungal infections in approximately one third of patients. Therefore surveillance cultures are recommended by the AASLD routinely for early detection and treatment for infections.<sup><xref ref-type="bibr" rid="bibr37-1944451612444444">37</xref>,<xref ref-type="bibr" rid="bibr38-1944451612444444">38</xref></sup></p>
<p>Prophylactic antibiotics are often used to prevent the progression from encephalopathy to SIRS. However the AASLD does not recommend the use of prophylactic antibiotics and antifungals in patients with ALF, especially in those with mild hepatic encephalopathy, as they have not been shown to improve outcomes.<sup><xref ref-type="bibr" rid="bibr37-1944451612444444">37</xref></sup> However, once the patient is listed for OLT, empiric antibiotics are recommended as the presence of infection may cause the patient to be delisted.<sup><xref ref-type="bibr" rid="bibr38-1944451612444444">38</xref></sup></p>
</sec>
<sec id="section17-1944451612444444">
<title>Thiopental and Pentobarbital</title>
<p>Thiopental and pentobarbital are centrally acting hypnotics that cause a reduction in brain oxygen utilization and are considered second-line therapy for severe ICH.<sup><xref ref-type="bibr" rid="bibr38-1944451612444444">38</xref></sup> Continuous electroencephalographic monitoring for dose titration is necessary during administration. Systemic hypotension is a common complication and therefore blood pressure support may be necessary to maintain adequate CPP. Cardiac arrhythmias and immune suppression may also occur increasing the risk of infection and ileus.<sup><xref ref-type="bibr" rid="bibr38-1944451612444444">38</xref></sup></p>
</sec>
<sec id="section18-1944451612444444">
<title>Vitamin K and Clotting Factors</title>
<p>A number of factors are involved in the bleeding and clotting diatheses present in ALF, which include quantitative and qualitative platelet dysfunction, a deficiency in factors II, V, VII, IX, and X, a reduction in fibrinolytic proteins, increased plasminogen activator inhibitor-1, reduced antithrombin III, and proteins C and S, and possibly a deficiency in vitamin K. Administration of vitamin K may be considered in addition to blood products such as FFP, cryoprecipitate and platelets to help coagulopathy.<sup><xref ref-type="bibr" rid="bibr38-1944451612444444">38</xref></sup> Intravenous administration is the preferred route as the oral form of vitamin K is poorly absorbed, particularly in patients with bowel wall edema or cholestatic jaundice. Recombinant factor VIIa (rVIIa) may also be recommended as off-label use for patients who do not respond to fresh frozen plasma (FFP) or cannot receive FFP secondary to volume overload or risk for adverse reaction. The duration of action for rVIIa is 2 to 6 hours. Side effects include thrombotic risk, and it is contraindicated in patients who have had a prior myocardial infarction, ischemic stroke, pulmonary embolism, ALF from pregnancy, acute portal vein thrombosis, and Budd–Chiari syndrome.<sup><xref ref-type="bibr" rid="bibr38-1944451612444444">38</xref></sup></p>
</sec>
<sec id="section19-1944451612444444">
<title>Liver Transplantation</title>
<p>Acute liver failure accounts for approximately 10% of the liver transplantation in the United States, and OLT is the only therapy that has proven benefit with 1-year survival rates of greater than 80% (whole organ).<sup><xref ref-type="bibr" rid="bibr39-1944451612444444">39</xref>,<xref ref-type="bibr" rid="bibr40-1944451612444444">40</xref></sup> The option of living donor liver transplantation is also available at some transplant centers and may provide a faster pathway to transplantation.</p>
<p>As discussed, the necessity to transfer patients to a transplant facility for listing, as a status 1A recipient by the United Network for Organ Sharing is vital to give patients the best chance of survival. Further factors such as preexisting undertreated medical or psychiatric conditions, adequacy of social support, and ongoing substance abuse will also be assessed by the transplant team to determine candidacy.<sup><xref ref-type="bibr" rid="bibr41-1944451612444444">41</xref></sup></p>
<p>It is difficult to predict survival based on any given single factor in ALF. Several prognostic models for patients with ALF have been published but these studies were not able to accurately predict outcome and to determine exactly who should progress to OLT.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref>,<xref ref-type="bibr" rid="bibr42-1944451612444444">42</xref></sup> Thus, the most recent report by the AASLD in 2011 recommends using a multifactorial approach based on the factors of reversibility of the etiology, severity of hepatic encephalopathy, and an assessment of the ability for hepatic regeneration be used to guide the decision for proceeding to transplant versus waiting in those with a good chance of survival without OLT.<sup><xref ref-type="bibr" rid="bibr6-1944451612444444">6</xref></sup> The Kings Hospital Criteria listed in <xref ref-type="table" rid="table4-1944451612444444">Table 4</xref> address acetaminophen and non-acetaminophen criteria for OLT.<sup><xref ref-type="bibr" rid="bibr43-1944451612444444">43</xref></sup></p>
<table-wrap id="table4-1944451612444444" position="float">
<label>Table 4.</label>
<caption>
<p>Kings Hospital Criteria for Patients in Case of Acute Liver Failure</p>
</caption>
<graphic alternate-form-of="table4-1944451612444444" xlink:href="10.1177_1944451612444444-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td colspan="3">Acetaminophen-induced liver failure</td>
</tr>
<tr>
<td> Arterial</td>
<td>OR</td>
<td>Grade III or IV encephalopathy</td>
</tr>
<tr>
<td>  pH &lt; 7.3</td>
<td/>
<td>AND</td>
</tr>
<tr>
<td/>
<td/>
<td>Prothrombin time &gt;100 seconds</td>
</tr>
<tr>
<td/>
<td/>
<td>AND</td>
</tr>
<tr>
<td/>
<td/>
<td>Serum creatinine &gt;3.4 mg/dL</td>
</tr>
<tr>
<td colspan="3">Other etiology acute liver failure</td>
</tr>
<tr>
<td> Prothrombin  time &gt;100  seconds</td>
<td>OR</td>
<td>Any 3 of the following:<list id="list1-1944451612444444" list-type="order">
<list-item><p>Age &lt;10 years or &gt;40 years</p></list-item>
<list-item><p>Etiology: non-A or non-B hepatitis, halothane hepatitis, idiosyncratic drug reactions</p></list-item>
<list-item><p>Duration of jaundice before onset of encephalopathy &gt;7 days</p></list-item>
<list-item><p>Prothrombin time &gt;50 seconds</p></list-item>
<list-item><p>Serum bilirubin &gt;18 mg/dL</p></list-item>
</list></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section20-1944451612444444">
<title>Liver Support Systems</title>
<p>Liver support systems, although uncommon, can offer ALF patients a bridge to transplantation or recovery. These systems are divided into 2 categories; noncell and cell based.</p>
<p>Noncell-based systems include plasmapheresis, hemodialysis, and albumin-based extracorporeal adsorption methods. Cell-based systems provide hepatic synthetic support by incorporating hepatocytes into plasmapheresis or whole blood extracorporeal systems.<sup><xref ref-type="bibr" rid="bibr44-1944451612444444">44</xref></sup> Current cell- and noncell-based systems undergoing clinical trials include (<italic>a</italic>) extracorporeal liver assist device (ELAD) using human hepatocytes<sup><xref ref-type="bibr" rid="bibr45-1944451612444444">45</xref></sup>; (<italic>b</italic>) 2 systems using porcine hepatocytes—bioartificial extracorporeal liver support system (BELS) and the HepatAssist liver support system<sup><xref ref-type="bibr" rid="bibr46-1944451612444444">46</xref>,<xref ref-type="bibr" rid="bibr47-1944451612444444">47</xref></sup>; (<italic>c</italic>) the molecular adsorbents recirculation system (MARS) using albumin dialysis<sup><xref ref-type="bibr" rid="bibr48-1944451612444444">48</xref></sup>; and (<italic>d</italic>) Prometheus, an extracorporeal device using a special adsorber to remove albumin-bound substances with high-flux hemodialysis.<sup><xref ref-type="bibr" rid="bibr49-1944451612444444">49</xref></sup></p>
</sec>
</sec>
<sec id="section21-1944451612444444" sec-type="conclusions">
<title>Conclusion</title>
<p>Despite advances in the management of critically ill patients, the diagnosis of ALF, although rare, carries a high mortality rate. Survival can be improved by early identification of the etiology, immediate initiation of NAC, early empiric broad-spectrum antibiotics, and aggressive management of the sequelae associated with ALF.</p>
<p>Ultimately, these patients are best served at tertiary care facilities that specialize in liver transplantation. Early transfer, while the patient remains hemodynamically and neurologically stable, can ensure timely evaluation for liver transplantation—the only proven therapy for patients with ALF. A multidisciplinary approach, including hepatologists, transplant surgeons, and critical care providers can improve quality of care both before and after transplantation and lead to improved overall outcomes from this potentially devastating condition.</p>
</sec>
</body>
<back>
<ack><p>The authors would like to acknowledge and express thanks to the Hepatology, Transplant Surgery, and Pulmonary Group at California Pacific Medical Center. Their commitment to education and learning has improved care of this patient population in our critical care unit.</p></ack>
<fn-group>
<fn fn-type="conflict">
<p>The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1944451612444444">
<label>1.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>WM</given-names></name>
<name><surname>Squires</surname><given-names>RH</given-names><suffix>Jr</suffix></name>
<name><surname>Nyberg</surname><given-names>SL</given-names></name>
<name><surname>Doo</surname><given-names>E</given-names></name>
<name><surname>Hoofnagle</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Acute liver failure: summary of a workshop</article-title>. <conf-name>Hepatology</conf-name>. <year>2008</year>;<volume>47</volume>:<fpage>1401</fpage>-<lpage>1415</lpage>.</citation>
</ref>
<ref id="bibr2-1944451612444444">
<label>2.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Trey</surname><given-names>C</given-names></name>
<name><surname>Davidson</surname><given-names>CS</given-names></name>
</person-group>. <article-title>The management of fulminant hepatic failure</article-title>. In: <person-group person-group-type="editor">
<name><surname>Popper</surname><given-names>H</given-names></name>
<name><surname>Schaffner</surname><given-names>F</given-names></name>
</person-group>, eds. <source>Progress in Liver Diseases</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Grune &amp; Stratton</publisher-name>, <volume>1970</volume>:<fpage>282</fpage>-<lpage>298</lpage>.</citation>
</ref>
<ref id="bibr3-1944451612444444">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Grady</surname><given-names>JG</given-names></name>
<name><surname>Schalm</surname><given-names>SW</given-names></name>
<name><surname>Williams</surname><given-names>R</given-names></name>
</person-group>. <article-title>Acute liver failure: redefining the syndromes</article-title>. <source>Lancet</source>. <year>1993</year>;<volume>342</volume>:<fpage>273</fpage>-<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr4-1944451612444444">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ostapowicz</surname><given-names>G</given-names></name>
<name><surname>Fontana</surname><given-names>RJ</given-names></name>
<name><surname>Schiødt</surname><given-names>FV</given-names></name><etal/>
</person-group>; <collab>U.S. Acute Liver Failure Study Group</collab>. <article-title>Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States</article-title>. <source>Ann Intern Med</source>. <year>2002</year>;<volume>137</volume>:<fpage>947</fpage>-<lpage>954</lpage>.</citation>
</ref>
<ref id="bibr5-1944451612444444">
<label>5.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Sood</surname><given-names>GK</given-names></name>
<name><surname>Conrad</surname><given-names>SA</given-names></name>
<name><surname>Luu</surname><given-names>L</given-names></name>
<name><surname>Slabinski</surname><given-names>MS</given-names></name>
<name><surname>Van Gelder</surname><given-names>CM</given-names></name>
</person-group>. <article-title>Acute liver failure</article-title>. <ext-link ext-link-type="uri" xlink:href="http://emedicine.medscape.com/article/177354-overview#aw2aab6b2b3aa">http://emedicine.medscape.com/article/177354-overview#aw2aab6b2b3aa</ext-link>. <access-date>Accessed January 11, 2011</access-date>.</citation>
</ref>
<ref id="bibr6-1944451612444444">
<label>6.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>WM</given-names></name>
<name><surname>Larson</surname><given-names>AM</given-names></name>
<name><surname>Stravitz</surname><given-names>RT</given-names></name>
</person-group>. <article-title>AASLD position paper: the management of acute liver failure: update 2011</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf">http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf</ext-link>. <access-date>Accessed November 17, 2011</access-date>.</citation>
</ref>
<ref id="bibr7-1944451612444444">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bernal</surname><given-names>W</given-names></name>
<name><surname>Auzinger</surname><given-names>G</given-names></name>
<name><surname>Dhawan</surname><given-names>A</given-names></name>
<name><surname>Wendon</surname><given-names>J</given-names></name>
</person-group>. <article-title>Acute liver failure</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>376</volume>:<fpage>190</fpage>-<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr8-1944451612444444">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korman</surname><given-names>JD</given-names></name>
<name><surname>Volenberg</surname><given-names>I</given-names></name>
<name><surname>Balko</surname><given-names>J</given-names></name><etal/>
</person-group>; <collab>Pediatric and Adult Acute Liver Failure Study Groups</collab>. <article-title>Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests</article-title>. <source>Hepatology</source>. <year>2008</year>;<volume>48</volume>:<fpage>1167</fpage>-<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr9-1944451612444444">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>SS</given-names></name>
<name><surname>Cheng</surname><given-names>KS</given-names></name>
<name><surname>Lai</surname><given-names>YC</given-names></name><etal/>
</person-group>. <article-title>Decreasing serum alpha-fetoprotein levels in predicting poor prognosis of acute hepatic failure in patients with chronic hepatitis</article-title> <source>Br J Gastroenterol</source>. <year>2002</year>;<volume>37</volume>:<fpage>626</fpage>-<lpage>632</lpage>.</citation>
</ref>
<ref id="bibr10-1944451612444444">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>LE</given-names></name>
<name><surname>Dalhoff</surname><given-names>K</given-names></name>
</person-group>. <article-title>Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury</article-title>. <source>Hepatology</source>. <year>2005</year>;<volume>41</volume>:<fpage>26</fpage>-<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr11-1944451612444444">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schiødt</surname><given-names>FV</given-names></name>
<name><surname>Ostapowicz</surname><given-names>G</given-names></name>
<name><surname>Murray</surname><given-names>N</given-names></name><etal/>
</person-group>. <article-title>Alpha-fetoprotein and prognosis in acute liver failure</article-title>. <source>Liver Transpl</source>. <year>2006</year>;<volume>12</volume>:<fpage>1776</fpage>-<lpage>1781</lpage>.</citation>
</ref>
<ref id="bibr12-1944451612444444">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Elinav</surname><given-names>E</given-names></name>
<name><surname>Ben-Dov</surname><given-names>I</given-names></name>
<name><surname>Hai-Am</surname><given-names>E</given-names></name>
<name><surname>Ackerman</surname><given-names>Z</given-names></name>
<name><surname>Ofran</surname><given-names>Y</given-names></name>
</person-group>. <article-title>The predictive value of admission and follow up factor V and VII levels in patients with acute hepatitis and coagulopathy</article-title>. <source>J Hepatol</source>. <year>2005</year>;<volume>42</volume>:<fpage>82</fpage>-<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr13-1944451612444444">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clemmesen</surname><given-names>JO</given-names></name>
<name><surname>Larsen</surname><given-names>FS</given-names></name>
<name><surname>Kondrup</surname><given-names>J</given-names></name>
<name><surname>Hansen</surname><given-names>BA</given-names></name>
<name><surname>Ott</surname><given-names>P</given-names></name>
</person-group>. <article-title>Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration</article-title>. <source>Hepatology</source>. <year>1999</year>;<volume>29</volume>:<fpage>648</fpage>-<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr14-1944451612444444">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhatia</surname><given-names>V</given-names></name>
<name><surname>Singh</surname><given-names>R</given-names></name>
<name><surname>Acharya</surname><given-names>SK</given-names></name>
</person-group>. <article-title>Predictive value of arterial ammonia for complications and outcome in acute liver failure</article-title>. <source>Gut</source>. <year>2006</year>;<volume>55</volume>:<fpage>98</fpage>-<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr15-1944451612444444">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nino-Murcia</surname><given-names>M</given-names></name>
<name><surname>Ralls</surname><given-names>PW</given-names></name>
<name><surname>Jeffrey</surname><given-names>RB</given-names><suffix>Jr</suffix></name>
<name><surname>Johnson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Color flow Doppler characterization of focal hepatic lesions</article-title>. <source>AJR Am J Roentgenol</source>. <year>1992</year>;<volume>159</volume>:<fpage>1195</fpage>-<lpage>1197</lpage>.</citation>
</ref>
<ref id="bibr16-1944451612444444">
<label>16.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Kaplan</surname><given-names>M</given-names></name>
</person-group>. <article-title>Interpretation of liver biopsy specimens</article-title>. <source>UpToDate</source>. <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com/contents/interpretation-of-liver-biopsy-specimens?source=search_result&amp;search=Interpretation+of+liver+biopsy+specimens&amp;selectedTitle=1%7E150">http://www.uptodate.com/contents/interpretation-of-liver-biopsy-specimens?source=search_result&amp;search=Interpretation+of+liver+biopsy+specimens&amp;selectedTitle=1%7E150</ext-link>. <access-date>Accessed February 6, 2012</access-date>.</citation>
</ref>
<ref id="bibr17-1944451612444444">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miraglia</surname><given-names>R</given-names></name>
<name><surname>Luca</surname><given-names>A</given-names></name>
<name><surname>Gruttadauria</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Contribution of transjugular liver biopsy in patients with the clinical presentation of acute liver failure</article-title>. <source>Cardiovasc Intervent Radiol</source>. <year>2006</year>;<volume>29</volume>:<fpage>1008</fpage>-<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr18-1944451612444444">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Esposito</surname><given-names>AA</given-names></name>
<name><surname>Nicolini</surname><given-names>A</given-names></name>
<name><surname>Meregaglia</surname><given-names>D</given-names></name>
<name><surname>Sangiovanni</surname><given-names>A</given-names></name>
<name><surname>Biondetti</surname><given-names>P</given-names></name>
</person-group>. <article-title>Role of transjugular liver biopsy in the diagnostic and therapeutic management of patients with severe liver disease</article-title>. <source>Radiol Med</source>. <year>2008</year>;<volume>113</volume>:<fpage>1008</fpage>-<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr19-1944451612444444">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shawcross</surname><given-names>DL</given-names></name>
<name><surname>Wendon</surname><given-names>JA</given-names></name>
</person-group>. <article-title>The neurological manifestations of acute liver failure</article-title> [<comment>published online ahead of print November 2, 2011</comment>]. <source>Neurochem Int</source>. <comment>In press</comment>.</citation>
</ref>
<ref id="bibr20-1944451612444444">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chavarria</surname><given-names>L</given-names></name>
<name><surname>Alonso</surname><given-names>J</given-names></name>
<name><surname>Rovira</surname><given-names>A</given-names></name>
<name><surname>Córdoba</surname><given-names>J</given-names></name>
</person-group>. <article-title>Neuroimaging in acute liver failure</article-title>. <source>Neurochem Int</source>. <year>2011</year>;<volume>59</volume>:<fpage>1175</fpage>-<lpage>1180</lpage>.</citation>
</ref>
<ref id="bibr21-1944451612444444">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Donovan</surname><given-names>JP</given-names></name>
<name><surname>Shaw</surname><given-names>BW</given-names></name>
<name><surname>Langnas</surname><given-names>AN</given-names></name>
<name><surname>Sorrel</surname><given-names>MF</given-names></name>
</person-group>. <article-title>Brain water and acute liver failure: the emerging role of intracranial pressure monitoring</article-title>. <source>Hepatology</source>. <year>1992</year>;<volume>16</volume>:<fpage>267</fpage>-<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr22-1944451612444444">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doyle</surname><given-names>JA</given-names></name>
<name><surname>Davis</surname><given-names>DP</given-names></name>
<name><surname>Hoyt</surname><given-names>DB</given-names></name>
</person-group>. <article-title>The use of hypertonic saline in the treatment of traumatic brain injury</article-title>. <source>J Trauma</source>. <year>2001</year>;<volume>50</volume>:<fpage>367</fpage>-<lpage>383</lpage>.</citation>
</ref>
<ref id="bibr23-1944451612444444">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hariri</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Cerebral edema</article-title>. <source>Neurosurg Clin N Am</source>. <year>1994</year>;<volume>5</volume>:<fpage>687</fpage>-<lpage>706</lpage>.</citation>
</ref>
<ref id="bibr24-1944451612444444">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vialet</surname><given-names>R</given-names></name>
<name><surname>Albanèse</surname><given-names>J</given-names></name>
<name><surname>Thomachot</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2mL/kg 20% mannitol</article-title>. <source>Crit Care Med</source>. <year>2003</year>;<volume>31</volume>:<fpage>1683</fpage>-<lpage>1687</lpage>.</citation>
</ref>
<ref id="bibr25-1944451612444444">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stravitz</surname><given-names>RT</given-names></name>
<name><surname>Kramer</surname><given-names>AH</given-names></name>
<name><surname>Davern</surname><given-names>T</given-names></name><etal/>
</person-group>. <article-title>Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group</article-title>. <source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>:<fpage>2498</fpage>-<lpage>2508</lpage>.</citation>
</ref>
<ref id="bibr26-1944451612444444">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Larson</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Acute liver failure</article-title>. <source>Disease-a-Month</source>. <year>2008</year>;<volume>54</volume>:<fpage>457</fpage>-<lpage>485</lpage>.</citation>
</ref>
<ref id="bibr27-1944451612444444">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Makin</surname><given-names>A</given-names></name>
<name><surname>Williams</surname><given-names>R</given-names></name>
</person-group>. <article-title>The current management of paracetamol overdosage</article-title>. <source>Br J Clin Pract</source>. <year>1994</year>;<volume>48</volume>:<fpage>144</fpage>-<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr28-1944451612444444">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davenport</surname><given-names>A</given-names></name>
</person-group>. <article-title>Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure</article-title>. <source>Crit Care Med</source>. <year>1993</year>;<volume>21</volume>:<fpage>328</fpage>-<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr29-1944451612444444">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prescott</surname><given-names>LF</given-names></name>
<name><surname>Critchley</surname><given-names>JA</given-names></name>
</person-group>. <article-title>The treatment of acetaminophen poisoning</article-title>. <source>Annu Rev Pharmacol Toxicol</source>. <year>1983</year>;<volume>23</volume>:<fpage>87</fpage>-<lpage>101</lpage>.</citation>
</ref>
<ref id="bibr30-1944451612444444">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamlyn</surname><given-names>AN</given-names></name>
<name><surname>Douglas</surname><given-names>AP</given-names></name>
<name><surname>James</surname><given-names>O</given-names></name>
</person-group>. <article-title>The spectrum of paracetamol (acetaminophen) overdose: clinical and epidemiological studies</article-title>. <source>Postgrad Med J</source>. <year>1978</year>;<volume>54</volume>:<fpage>400</fpage>-<lpage>404</lpage>.</citation>
</ref>
<ref id="bibr31-1944451612444444">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rumack</surname><given-names>BH</given-names></name>
</person-group>. <article-title>Acetaminophen overdose in young children</article-title>. <source>Am J Dis Child</source>. <year>1984</year>;<volume>138</volume>:<fpage>428</fpage>-<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr32-1944451612444444">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>PM</given-names></name>
<name><surname>Wendon</surname><given-names>JA</given-names></name>
<name><surname>Gimson</surname><given-names>AES</given-names></name>
<name><surname>Alexander</surname><given-names>GJM</given-names></name>
<name><surname>Williams</surname><given-names>R</given-names></name>
</person-group>. <article-title>Improvement by aceytlcysteine of hemodynamics and oxygen transport in fulminant hepatic failure</article-title>. <source>N Engl J Med</source>. <year>1991</year>;<volume>324</volume>:<fpage>1852</fpage>-<lpage>1857</lpage></citation>
</ref>
<ref id="bibr33-1944451612444444">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rank</surname><given-names>N</given-names></name>
<name><surname>Christian</surname><given-names>M</given-names></name>
<name><surname>Haertel</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title><italic>N</italic>-Acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study</article-title>. <source>Crit Care Med</source>. <year>2000</year>;<volume>28</volume>:<fpage>3799</fpage>-<lpage>3807</lpage>.</citation>
</ref>
<ref id="bibr34-1944451612444444">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>WM</given-names></name>
<name><surname>Hynan</surname><given-names>LS</given-names></name>
<name><surname>Rossaro</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Intravenous <italic>N</italic>-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>:<fpage>856</fpage>-<lpage>864</lpage>.</citation>
</ref>
<ref id="bibr35-1944451612444444">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>WM</given-names></name>
<name><surname>Rossaro</surname><given-names>L</given-names></name>
<name><surname>Fontana</surname><given-names>RJ</given-names></name><etal/>
</person-group>. <article-title>Intravenous <italic>N</italic>-acetylcysteine improves spontaneous survival in early stage non-acetaminophen acute liver failure [abstract]</article-title>. <source>Hepatology</source>. <year>2007</year>;<volume>46</volume>(<supplement>suppl 1</supplement>):<fpage>79</fpage>.</citation>
</ref>
<ref id="bibr36-1944451612444444">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harry</surname><given-names>R</given-names></name>
<name><surname>Auzinger</surname><given-names>G</given-names></name>
<name><surname>Wendon</surname><given-names>J</given-names></name>
</person-group>. <article-title>The clinical importance of adrenal insufficiency in acute hepatic dysfunction</article-title>. <source>Hepatology</source>. <year>2002</year>;<volume>36</volume>:<fpage>395</fpage>-<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr37-1944451612444444">
<label>37.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>WM</given-names></name>
<name><surname>Larson</surname><given-names>AM</given-names></name>
<name><surname>Stravitz</surname><given-names>RT</given-names></name>
</person-group>. <article-title>Corrections to the AASLD position paper: the management of acute liver failure: update 2011</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf">http://www.aasld.org/practiceguidelines/Documents/AcuteLiverFailureUpdate2011.pdf</ext-link> <access-date>Accessed March 27, 2012</access-date>.</citation>
</ref>
<ref id="bibr38-1944451612444444">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sundaram</surname><given-names>V</given-names></name>
<name><surname>Shaikh</surname><given-names>OS</given-names></name>
</person-group>. <article-title>Acute liver failure: current practice and recent advances</article-title>. <source>Gastroenterol Clin N Am</source>. <year>2011</year>;<volume>40</volume>:<fpage>523</fpage>-<lpage>533</lpage>.</citation>
</ref>
<ref id="bibr39-1944451612444444">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lidofsky</surname><given-names>SD</given-names></name>
</person-group>. <article-title>Liver transplantation for fulminant hepatic failure</article-title>. <source>Gastroenterol Clin N Am</source>. <year>1993</year>;<volume>22</volume>:<fpage>257</fpage>-<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr40-1944451612444444">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Freeman</surname><given-names>RB</given-names><suffix>Jr</suffix></name>
<name><surname>Steffick</surname><given-names>DE</given-names></name>
<name><surname>Guidinger</surname><given-names>MK</given-names></name>
<name><surname>Farmer</surname><given-names>DG</given-names></name>
<name><surname>Berg</surname><given-names>CL</given-names></name>
<name><surname>Merion</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Liver and intestine transplantation in the United States, 1997-2006</article-title>. <source>Am J Transplant</source>. <year>2008</year>;<volume>8</volume>:<fpage>958</fpage>-<lpage>976</lpage>.</citation>
</ref>
<ref id="bibr41-1944451612444444">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simpson</surname><given-names>KJ</given-names></name>
<name><surname>Bates</surname><given-names>CM</given-names></name>
<name><surname>Henderson</surname><given-names>NC</given-names></name><etal/>
</person-group>. <article-title>The utilization of liver transplantation in the management of acute liver failure: comparison between acetaminophen and non-acetaminophen etiologies</article-title>. <source>Liver Transpl</source>. <year>2009</year>;<volume>15</volume>:<fpage>600</fpage>-<lpage>609</lpage>.</citation>
</ref>
<ref id="bibr42-1944451612444444">
<label>42.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Hoofnagle</surname><given-names>JH</given-names></name>
<name><surname>Carithers</surname><given-names>RL</given-names><suffix>Jr</suffix></name>
<name><surname>Shapiro</surname><given-names>C</given-names></name>
<name><surname>Ascher</surname><given-names>N</given-names></name>
</person-group>. <article-title>Fulminant hepatic failure: a summary of a workshop</article-title>. <conf-name>Hepatology</conf-name>. <year>1995</year>;<volume>21</volume>: <fpage>240</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr43-1944451612444444">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Grady</surname><given-names>JG</given-names></name>
<name><surname>Alexander</surname><given-names>GJ</given-names></name>
<name><surname>Hayllar</surname><given-names>KM</given-names></name>
<name><surname>Williams</surname><given-names>R</given-names></name>
</person-group>. <article-title>Early indicators of prognosis in fulminant hepatic failure</article-title>. <source>Gastroenterology</source>. <year>1989</year>;<volume>97</volume>:<fpage>439</fpage>-<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr44-1944451612444444">
<label>44.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Stevens</surname><given-names>AC</given-names></name>
</person-group>. <article-title>Liver support systems</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com/contents/liver-support-systems?view=print">http://www.uptodate.com/contents/liver-support-systems?view=print</ext-link>. <access-date>Accessed March 8, 2012</access-date>.</citation>
</ref>
<ref id="bibr45-1944451612444444">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sussman</surname><given-names>NL</given-names></name>
<name><surname>Gislason</surname><given-names>GT</given-names></name>
<name><surname>Conlin</surname><given-names>CA</given-names></name>
<name><surname>Kelly</surname><given-names>JH</given-names></name>
</person-group>. <article-title>The Hepatix extracorporeal liver assist device: initial clinical experience</article-title>. <source>Artif Organs</source>. <year>1994</year>;<volume>18</volume>:<fpage>390</fpage>-<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr46-1944451612444444">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerlach</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Long-term liver cell cultures in bioreactors and possible application for liver support</article-title>. <source>Cell Biol Toxicol</source>. <year>1997</year>;<volume>13</volume>:<fpage>349</fpage>-<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr47-1944451612444444">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samuel</surname><given-names>D</given-names></name>
<name><surname>Ichai</surname><given-names>P</given-names></name>
<name><surname>Feray</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation</article-title>. <source>Transplantation</source>. <year>2002</year>;<volume>73</volume>:<fpage>257</fpage>-<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr48-1944451612444444">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stange</surname><given-names>J</given-names></name>
<name><surname>Mitzner</surname><given-names>SR</given-names></name>
<name><surname>Klammt</surname><given-names>S</given-names></name><etal/>
</person-group>. <article-title>Liver support by extracorporeal blood purification: a clinical observation</article-title>. <source>Liver Transpl</source>. <year>2000</year>;<volume>6</volume>:<fpage>603</fpage>-<lpage>613</lpage>.</citation>
</ref>
<ref id="bibr49-1944451612444444">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rifai</surname><given-names>K</given-names></name>
<name><surname>Ernst</surname><given-names>T</given-names></name>
<name><surname>Kretschmer</surname><given-names>U</given-names></name><etal/>
</person-group>. <article-title>Prometheus—a new extracorporeal system for the treatment of liver failure</article-title>. <source>J Hepatol</source>. <year>2003</year>;<volume>39</volume>:<fpage>984</fpage>-<lpage>990</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>